Introduction
Mitochondria as "cellular power plants" generate cellular adenosine triphosphate through aerobic respiration.
In addition to energy, however, reactive oxygen species (ROS) with the potential to cause DNA damage are produced. 1 Each mitochondrion has 2 to 10 copies of mitochondrial DNA (mtDNA) which is a prime target of ROS damage because of the lack of protective histones, limited DNA repair mechanisms, and being in close proximity to the electron transport chain, which releases ROS. 2 Thus, the mutation rate of mtDNA has been reported to be up to 15-fold higher than for nuclear DNA in response to DNA damaging agents 3 such as UV, cigarette smoke, benzene and ionizing radiation. [4] [5] [6] It has been hypothesized that mitochondria function and mtDNA damage are involved in carcinogenesis. 7 Studies have suggested that mitochondria possibly increase the number of mtDNA copies to compensate for mtDNA damage and mitochondrial dysfunction. 1, 8, 9 Many of the mtDNA mutations found in human cancer samples are located in the D-loop region which, is involved in the control of replication and transcription of mtDNA and might cause an alteration in the copy number and/or gene expression of the mitochondrial genome. 10 Recent prospective studies have shown an association between increasing mtDNA copy number in peripheral blood and increased risk of B-cell non-Hodgkin lymphoma (B-NHL) 11 , lung cancer 12 , pancreatic cancer 13 , and colorectal cancer 14 , but not with gastric cancer 15 .
Lan and colleagues reported elevated mtDNA copy numbers of peripheral white blood cells in prediagnostic blood samples of healthy subjects that later in life developed B-NHL with a suggestion that the effect was most pronounced for chronic lymphocytic leukemia (CLL). 11 However, the study was limited by its relatively small sample size (CLL cases n=34) hampering firm conclusions on the subtype specific analyses.
Replication of these results in other prospective cohort studies with a larger number of B-NHL and especially CLL cases would provide additional evidence on the possible role of mtDNA function/damage in (CLL) lymphomagenesis.
In this study, we investigated the association between mtDNA copy number and incidence of Hodgkin lymphoma (HL), T-cell NHL (T-NHL), B-NHL and histologic subtypes among participants of the European Prospective Investigation into Cancer and nutrition Cohort (EPIC) study using a nested casecontrol design.
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Material and method

Study population
A detailed description of the EPIC cohort study can be found elsewhere. 16, 17 In the period 1992 to 2000, recruitment of over half a million (520,000) people in ten European countries (Denmark, France, Germany, Greece, Italy, The Netherlands, Norway, Spain, Sweden and the United Kingdom) was completed. The cohort includes participants of both genders, mostly in the age range 35-70 at recruitment. After providing informed consent, diet, lifestyle and personal medical history questionnaires were collected from most participants. Additionally, participants were invited to donate a blood sample. The EPIC study was approved by the review boards of the International Agency for Research on Cancer and by the local institutes in the participating countries. The study was conducted in accordance with the Declaration of Helsinki.
Follow-up for cancer incidence and vital status
Data on vital status in EPIC are collected through record linkage with regional and/or national mortality registries, except in Germany and Greece, where data are collected through active follow-up and checks through municipal population registries. Cancer incidence is determined through record linkage with regional cancer registries or via a combination of methods, including the use of health insurance records, contacts with pathology registries, and active follow-up through participants and their next of kin. For each incident lymphoma case, one random control was selected among all cohort members alive and free of cancer at the time of diagnosis of the index case matched by center, gender, date of recruitment (± 1 year), and age at recruitment (± 3 years). Through 1st August, 2008, a total of 483 lymphoma cases were identified who were eligible to be included in the study. Subjects whose blood
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mtDNA copy number assay
The mitochondrial copy number was calculated based on the copy number measurement of mitochondrial gene (NADH dehydrogenase, subunit 1, ND1) and nuclear gene (hemoglobin subunit beta, ). Laboratory personnel were blinded with regard to case-control status. Cases and their matched controls were assayed on the same plate in the same batch. Each DNA sample was analyzed in duplicate in the same run. A third measurement was performed only when a discrepancy between the duplicate mtDNA copy number values was observed.
Quality control (QC) samples were run with the case-control sets in each batch. Mean within and between batch coefficients of variation based on the QC samples were 7.7% and 3.6% respectively. Mean within batch coefficient of variation and the intra class coefficient of variation based on the duplicate measurements (n=130) was 11.4% and 0.84, respectively. One case and two controls along with the matched counterparts were excluded from the analysis due to missing measurements. The mtDNA copy number was determined successfully on 469 case-control pairs.
Statistical Analysis
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From Distributions of baseline characteristics for matched cases and controls were assessed by paired t test and chi-square test for continuous and categorical variables, respectively. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were estimated using conditional logistic regression (CLR) models. The mtDNA copy number was categorized into quartiles based on the distribution among controls, and modeled as a categorical variable. Tests for trend were calculated using the quartile number as a continuous variable.
The effect of smoking status (categorical; current, former and never smokers), physical activity (categorical; inactive, moderately inactive, moderately active, active), educational level as indicator of socioeconomic status (categorical; none, primary school, technical/professional school, secondary school, longer education), body mass index (BMI) (kg/m 2 , continuous), and alcohol intake at recruitment (grams/day; continuous) as potential confounding variables were examined for B-NHL and for the major subtypes separately. Most of the confounder variables did not change the mtDNA risk estimates in these analyses with more than 10% except for smoking status and educational level. Therefore, we used a unified model including these two variables for all analyses. Of note, results based on subtype specific models, including additional sub-type specific confounders and the unified model were essentially similar. In addition, the possible effect modification of smoking as a factor that induces oxidative stress was evaluated. We also investigated the possible associations by major histological subtypes of B-NHL and stratified by median follow-up time. In order to retain as much power as possible, for subtype analyses, unconditional logistic regression was used in which cases in each subtype were compared with all controls additionally adjusted for matching variables (i.e. country, center, gender, and age at recruitment) and plate number. We additionally investigated associations with mtDNA categories for B-NHL subtypes (i.e. chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), multiple myeloma (MM), other B-NHL) using polytomous regression models adjusted for age at recruitment, year of recruitment, sex, EPIC country, smoking status, educational level and plate number. Due to the slow growing nature of indolent lymphomas such as CLL, we repeated the analyses using a 3, 6, 9 years follow-up interval as sensitivity analyses.
Statistical analyses were performed using SAS (ver. 9.2, SAS institute). All p-values are two-sided, with p<0.05 considered as statistically significant.
Results
Description of the study population
The characteristics of the 469 lymphoma cases (231 men and 238 women) and an equal number of control subjects in this study are provided in Table 1 . Median time between recruitment (i.e., blood collection) in the study and diagnosis of lymphoma was 4.6 years (range, 0.02-14.3) (data not shown). Of all lymphoma cases, 418 were diagnosed with B-NHL, with the most common diagnosed subtypes being MM (n=109), CLL (n=102), FL (n=75) and DLBCL (N=60). There were 31 and 20 cases diagnosed with HL and T-NHL respectively. Case and control subjects were comparable in terms of age, BMI, smoking status, physical activity, and educational level. The mtDNA copy number was significantly higher in cases compared with controls ( 
Risk analyses
Risk for developing B-NHL increased significantly with increasing mtDNA copy number (Table 2, P trend=0.04). However, after adjustment for confounding variables, this result did not reach formal statistical significance. In subtype analyses of B-NHL including all control subjects (unconditional), the association was most pronounced for CLL (OR=1.34, 1.44 and 1.80 for quartiles 2-4, respectively P trend=0.002, Table 2 ).
Polytomous regression analyses were consistent with the logistic regression analyses showing a significant effect only for CLL (OR=1.56, 2.12 and 4.45 for quartiles 2-4, respectively P trend=0.001). Models excluding CLL cases showed no association between B-NHL and mtDNA copy number. Heterogeneity test by B-NHL subtype was significant (p=0.03). Moreover, we found no association between mtDNA and HL and T-NHL (data not shown). Stratified analyses by gender showed similar results in logistic regression (online material) and polytomous models (data not shown).
To determine if the association is driven in part by elevated mtDNA copy number among cases with undiagnosed, subclinical CLL at the time of blood sample collection, we additionally investigated the association stratified by median follow-up time. We found that mtDNA copy number significantly increased among cases diagnosed less than 4.6 years after blood collection which remained significant and of equal For personal use only. on April 12, 2017. by guest www.bloodjournal.org From magnitude among cases diagnosed more than 4.6 years after providing a blood sample (OR=1.40, 1.43 and 2.39 for quartiles 2-4, respectively P trend=0.05)( Table 3) . Heterogeneity test was not significant by median follow-up time for B-NHL (p= 0.62) and CLL (p=0.12). Moreover, sensitivity analyses of CLL by 3, 6, 9 years follow-up intervals showed significant increased risks of CLL in all these analyses (data not shown). No association was found between mtDNA copy number and follow-up time among B-NHL (p=0.21) and CLL cases (p=0.78). CLL subtype analyses stratified by median age at diagnosis (62 years) showed increased risks of CLL with elevated levels of mtDNA copy number among both groups with the association reaching statistical significance among cases diagnosed at an older age (OR=1.36, 1.40 and 3.21 for quartiles 2-4, respectively P trend=0.002 compared with OR=1.41, 1.42 and 2.00 for quartiles 2-4, respectively P trend=0.12).
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Discussion
In this prospective study, we found no significant association between mtDNA copy number and risk of developing B-cell lymphoma except for a strong significant positive association between higher mtDNA copy number and future CLL risk. The differential effect of mtDNA on B-cell lymphoma risk is in line with the current thinking that NHL consists of a heterogeneous group of tumors with distinct ontogenesis.
Lan et al 11 previously reported that elevated mtDNA copy number was associated with an increased risk of NHL and in particular CLL in a study of 104 incident male NHL cases and 104 matched controls within the prospective Alpha-Tocopherol, Beta-Carotene Cancer Prevention cohort. Our study with about three times the number of CLL cases and including both males and females confirms this association between mtDNA copy number and subsequent CLL risk. Stratified analyses by median follow-up time suggest furthermore that the increased risk can be observed long before diagnosis (> 4.6 years). Additional, analyses shifting the cut point progressively to 6 and 9 years showed still increased risks for cases diagnosed after 9 years of blood draw. Together with the observation that we did not observe an association between follow-up time and mtDNA levels among CLL cases, it would suggest that reversed causality is not a likely cause for the found association. However, as CLL is a chronic disease that often progresses slowly we cannot exclude fully that the observed effects are due to a precursor stage of CLL (i.e. monoclonal B-cell lymphocytosis). Our analyses furthermore would suggest that the association between mtDNA and CLL is stronger for cases diagnosed at an older age.
The largest meta-analysis on CLL including four genome-wide association studies identified several SNPs near to genes involved in apoptosis which suggests a possible underlying mechanism of biological relevance. 19 The two identified SNPs at 18q21.33 map to the 3′ UTR of BCL2 (B-cell CLL/lymphoma 2), which encodes an essential outer mitochondrial membrane protein that blocks lymphocyte apoptosis. Both
SNPs are located within a narrow region of BCL2 in which the majority of t (14;18) Alteration in intracellular levels of ROS is associated with changes in mitochondrial abundance, mtDNA copy number, and expression of respiratory genes. 1 However, the outcome of the events leading to the increase in mitochondrial abundance and mtDNA copy number is dependent on the level of oxidative stress, the capacity of the intracellular antioxidants system, and the quality of mitochondria and mtDNA. 1 Tumorigenesis requires active mitochondrial biogenesis to support high proliferation activity. It is noteworthy that increased mtDNA copy number has been detected in tumour cells from patients with CLL 22 , in Burkitt lymphoma cell lines, and in lymphoblastoid cell lines. 23 As such the observation of pre-clinical elevations in mtDNA levels in PBMCs seems of clinical relevance. Furthermore, mtDNA copy number has been shown to be increased in workers exposed to benzene 24 , an established leukemogen and suspected lymphomagen.
As such, it seems that mitochondrial biogenesis is biologically plausible pathway in lymphomagenesis.
The major strength of our study is that the biological samples were collected prospectively, before lymphoma diagnosis, from a large population, including both genders. Our study also has limitations. We did not have repeated measures of mtDNA copy number over the time and a single measurement may not reflect mtDNA copy number status over a lifetime. In addition, it is not possible to distinguish whether the increased mitochondrial copy number (MCN) in one cell is due to the increased mitochondria (constant MCN in each mitochondrion) or is due to the increased mtDNA replication without increased mitochondrial number. Indeed, the increase in MCN in a cell can indicate both increased mitochondrial mass and/or mtDNA replication. Moreover, due to the slow growing nature of indolent lymphomas such as CLL in which subclinical disease can be present for decades before diagnosis, we cannot exclude that we might have observed some epiphenomenon related to the presence of early disease stages even among subjects with more than 4.6 years between blood collection and diagnosis. Although we did not observe any trend among CLL cases between mtDNA copy number and follow-up time; we cannot dismiss that the observed association might be caused by indolent (pre-clinical) disease, especially as the relation between mtDNA and lymphoma was only seen for CLL which of all lymphoma subtypes is the most indolent. Finally, it is possible that some controls had undiagnosed subclinical CLL at the time of blood collection. However, given that CLL is a rare disease, bias due to individuals with undiagnosed CLL would be unlikely.
In conclusion, we observed that mtDNA copy number was strongly associated with increased risk of CLL. Although, the biological significance is yet to be clarified this may lead to a better understanding of mitochondrial function and damage in lymphomagenesis, in particular in the development of chronic lymphocytic leukemia.
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The mtDNA copy number (per diploid genome) was categorized into quartiles (Q) based on the distribution among controls, and modeled as categorical variable; Q number (minimum-maximum); P trend = p-value (two sided) were calculated by including the quartile number as continuous variable.
* Conditional logistic regression model adjusted for smoking status and education level was used for B-NHL and an unconditional logistic regression model adjusted for age at recruitment, sex, country, smoking status, educational level, and plate number was used for subtype analyses.
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